Iometopane

Drug Profile

Iometopane

Alternative Names: 123I β-CIT; Dopascan; GPI-200; RTI-55

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RTI International
  • Developer Daiichi Radioisotope Labs; MGI GP
  • Class Radiopharmaceutical diagnostics; Small molecules; Tropanes
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 28 Oct 2005 Guilford Pharmaceuticals is now called MGI GP
  • 05 Oct 2005 Guilford Pharmaceuticals has been acquired by MGI Pharma
  • 23 Aug 2005 Schering AG has terminated the license agreement for iometopane
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top